



1Fw 1614  
Patent Application  
Attorney Docket No. PC10370A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop Amendment, Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 29th day of April, 2005.

By

*Kelly A. Smith*

(Signature of person mailing)  
Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ghazwan Saleem Butrous :

APPLICATION NO.: 09/692,807 : Examiner: Dwayne C. Jones

FILING DATE: October 20, 2000 : Group Art Unit: 1614

TITLE: TREATMENT OF PULMONARY  
HYPERTENSION :

Mail Stop Amendment

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the reference cited by the applicant(s), a copy of which is enclosed. This reference was cited by the Applicants on November 1, 2004, but an English translation was not available at that time. Applicants herein submit the English translation of WO 99/29646.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 CFR 1.97(c) and 1.17(p). The Commissioner is further authorized to charge any additional fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.


INFORMATION DISCLOSURE STATEMENT, 9/99, (1/2)

A prompt and favorable response is earnestly solicited.

Date: \_\_\_\_\_

4/28/05

Respectfully submitted,



A. Dean Olson  
Attorney for Applicant(s)  
Reg. No. 31,185

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 441-4904



<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC10370A				SERIAL NO. 09/692,807						
				APPLICANT Ghazwan Saleem Butrous										
				FILING DATE October 20, 2000				GROUP 1614						
<b>U.S. PATENT DOCUMENTS</b>														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	9	9	2	6	9	4	6	6/3/99	International	C07D	471/04	x	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
<b>EXAMINER</b> <span style="float: right;"><b>DATE CONSIDERED</b></span>														
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														